_id
690db566ccc777a4e85d0db7
Ticker
BBOT
Name
BridgeBio Oncology Therapeutics, Inc.
Exchange
NASDAQ
Address
256 E. Grand Avenue, South San Francisco, CA, United States, 94080
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://bbotx.com
Description
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
Last Close
11.39
Volume
40319
Current Price
11.58
Change
0.165
Last Updated
2026-01-20T16:16:04.603Z
Image
data:image/webp;base64,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
Ipo Date
2025-08-12T00:00:00.000Z
Market Cap
1005006272
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.49375
Sentiment Sources
4
Rating
4.17
Strong Buy
1
Buy
5
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
49181000
Operating Income
-49181000
Interest Expense
-
Pretax Income
-44757000
Net Income
-44757000
Eps
-1.9038240673784508
Dividends Per Share
-
Shares Outstanding
79196710
Income Tax Expense
-
EBITDA
-49000000
Operating Margin
-
Total Other Income Expense Net
4424000
Cash
408741000
Short Term Investments
59544000
Receivables
226000
Inventories
-
Total Current Assets
476010000
Property Plant Equipment
3267000
Total Assets
484793000
Payables
3650000
Short Term Debt
506000
Long Term Debt
-
Total Liabilities
38093000
Equity
446700000
Bs_currency_symbol
USD
Depreciation
416000
Change In Working Capital
10415116
Cash From Operations
-70626454
Capital Expenditures
532996
Cash From Investing
65562000
Cash From Financing
383988000
Net Change In Cash
408076769
Cf_currency_symbol
USD
PE
-
PB
0.6094341168569509
ROE
-10.019476158495634
ROA
-9.232187758486612
FCF
-71159450
Fcf Percent
-
Piotroski FScore
0
Health Score
41
Deep Value Investing Score
6
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
4
Net Net Investing Score
3
Quality Investing Score
3
Value Investing Score
5.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
49181000
Quarters > 0 > income Statement > operating Income
-49181000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-44757000
Quarters > 0 > income Statement > net Income
-44757000
Quarters > 0 > income Statement > eps
-1.9038240673784508
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
23509000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-49000000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
4424000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
408741000
Quarters > 0 > balance Sheet > short Term Investments
59544000
Quarters > 0 > balance Sheet > receivables
226000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
476010000
Quarters > 0 > balance Sheet > property Plant Equipment
3267000
Quarters > 0 > balance Sheet > total Assets
484793000
Quarters > 0 > balance Sheet > payables
3650000
Quarters > 0 > balance Sheet > short Term Debt
506000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
38093000
Quarters > 0 > balance Sheet > equity
446700000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-44757000
Quarters > 0 > cash Flow > depreciation
416000
Quarters > 0 > cash Flow > change In Working Capital
10415116
Quarters > 0 > cash Flow > cash From Operations
-70626454
Quarters > 0 > cash Flow > capital Expenditures
532996
Quarters > 0 > cash Flow > cash From Investing
65562000
Quarters > 0 > cash Flow > cash From Financing
383988000
Quarters > 0 > cash Flow > net Change In Cash
408076769
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-1.9038240673784508
Quarters > 0 > ratios > PB
0.6094341168569509
Quarters > 0 > ratios > ROE
-10.019476158495634
Quarters > 0 > ratios > ROA
-9.232187758486612
Quarters > 0 > ratios > FCF
-71159450
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
41
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
30093000
Quarters > 1 > income Statement > operating Income
-30093000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-28435000
Quarters > 1 > income Statement > net Income
-28435000
Quarters > 1 > income Statement > eps
-1.2095367731507083
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
23509000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-29912000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
1658000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
31518000
Quarters > 1 > balance Sheet > short Term Investments
99880000
Quarters > 1 > balance Sheet > receivables
1077000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
142346000
Quarters > 1 > balance Sheet > property Plant Equipment
3449000
Quarters > 1 > balance Sheet > total Assets
151253000
Quarters > 1 > balance Sheet > payables
2197000
Quarters > 1 > balance Sheet > short Term Debt
320000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
378986000
Quarters > 1 > balance Sheet > equity
-227733000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-28435000
Quarters > 1 > cash Flow > depreciation
181000
Quarters > 1 > cash Flow > change In Working Capital
4475000
Quarters > 1 > cash Flow > cash From Operations
-23293000
Quarters > 1 > cash Flow > capital Expenditures
231000
Quarters > 1 > cash Flow > cash From Investing
9639000
Quarters > 1 > cash Flow > cash From Financing
18956000
Quarters > 1 > cash Flow > net Change In Cash
5302000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.2095367731507083
Quarters > 1 > ratios > PB
-1.195409624428607
Quarters > 1 > ratios > ROE
12.486113123701879
Quarters > 1 > ratios > ROA
-18.799627114834085
Quarters > 1 > ratios > FCF
-23524000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
33
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
23137000
Quarters > 2 > income Statement > operating Income
-23137000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-22055000
Quarters > 2 > income Statement > net Income
-22055000
Quarters > 2 > income Statement > eps
-0.9381513462929091
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
23509000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-23083000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
1082000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
963135
Quarters > 2 > balance Sheet > short Term Investments
109501000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
1239393
Quarters > 2 > balance Sheet > property Plant Equipment
3359000
Quarters > 2 > balance Sheet > total Assets
195677952
Quarters > 2 > balance Sheet > payables
1783561
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
7390744
Quarters > 2 > balance Sheet > equity
188287208
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-487392
Quarters > 2 > cash Flow > depreciation
54000
Quarters > 2 > cash Flow > change In Working Capital
20244
Quarters > 2 > cash Flow > cash From Operations
-734642
Quarters > 2 > cash Flow > capital Expenditures
162000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-404000
Quarters > 2 > cash Flow > net Change In Cash
-734642
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.9381513462929091
Quarters > 2 > ratios > PB
1.445845540393801
Quarters > 2 > ratios > ROE
-11.713488257789663
Quarters > 2 > ratios > ROA
-11.271070539413659
Quarters > 2 > ratios > FCF
-896642
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
43
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
21879000
Quarters > 3 > income Statement > operating Income
-21879000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-19687000
Quarters > 3 > income Statement > net Income
-19687000
Quarters > 3 > income Statement > eps
-1.183397451310411
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
16636000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-21827000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
2192000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
1697777
Quarters > 3 > balance Sheet > short Term Investments
124780000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
1949777
Quarters > 3 > balance Sheet > property Plant Equipment
490000
Quarters > 3 > balance Sheet > total Assets
194424196
Quarters > 3 > balance Sheet > payables
3074000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
5707515
Quarters > 3 > balance Sheet > equity
188716681
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
1953176
Quarters > 3 > cash Flow > depreciation
52000
Quarters > 3 > cash Flow > change In Working Capital
127452
Quarters > 3 > cash Flow > cash From Operations
-87859
Quarters > 3 > cash Flow > capital Expenditures
10000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
52000
Quarters > 3 > cash Flow > net Change In Cash
-87859
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.183397451310411
Quarters > 3 > ratios > PB
1.020815324745988
Quarters > 3 > ratios > ROE
-10.432040186209083
Quarters > 3 > ratios > ROA
-10.125797305598732
Quarters > 3 > ratios > FCF
-97859
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
43
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
80863000
Annuals > 0 > income Statement > operating Income
-80863000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-74275000
Annuals > 0 > income Statement > net Income
-74275000
Annuals > 0 > income Statement > eps
-4.4647150757393606
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
16636000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-80655000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
6588000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
1697777
Annuals > 0 > balance Sheet > short Term Investments
124780000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
1949777
Annuals > 0 > balance Sheet > property Plant Equipment
490000
Annuals > 0 > balance Sheet > total Assets
194424196
Annuals > 0 > balance Sheet > payables
3074000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
5707515
Annuals > 0 > balance Sheet > equity
188716681
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
7599512
Annuals > 0 > cash Flow > depreciation
208000
Annuals > 0 > cash Flow > change In Working Capital
-104613
Annuals > 0 > cash Flow > cash From Operations
-763820
Annuals > 0 > cash Flow > capital Expenditures
49000
Annuals > 0 > cash Flow > cash From Investing
-184000000
Annuals > 0 > cash Flow > cash From Financing
186461597
Annuals > 0 > cash Flow > net Change In Cash
1697777
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-4.4647150757393606
Annuals > 0 > ratios > PB
1.020815324745988
Annuals > 0 > ratios > ROE
-39.357941018473085
Annuals > 0 > ratios > ROA
-38.20254964562127
Annuals > 0 > ratios > FCF
-812820
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
35
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
64771000
Annuals > 1 > income Statement > operating Income
-64771000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-64699000
Annuals > 1 > income Statement > net Income
-64699000
Annuals > 1 > income Statement > eps
-3.1583597754454478
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
20485000
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-64679000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
72000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
250000
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
3937000
Annuals > 1 > balance Sheet > property Plant Equipment
596000
Annuals > 1 > balance Sheet > total Assets
332894
Annuals > 1 > balance Sheet > payables
575000
Annuals > 1 > balance Sheet > short Term Debt
70095
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
396463
Annuals > 1 > balance Sheet > equity
-63569
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-41692
Annuals > 1 > cash Flow > depreciation
92000
Annuals > 1 > cash Flow > change In Working Capital
15000
Annuals > 1 > cash Flow > cash From Operations
-52079000
Annuals > 1 > cash Flow > capital Expenditures
414000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
55124000
Annuals > 1 > cash Flow > net Change In Cash
225000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-3.1583597754454478
Annuals > 1 > ratios > PB
-3731.634916390064
Annuals > 1 > ratios > ROE
101777.59599804936
Annuals > 1 > ratios > ROA
-19435.31574615343
Annuals > 1 > ratios > FCF
-52493000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
-
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
3520
Annuals > 2 > income Statement > operating Income
-3520
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-3520
Annuals > 2 > income Statement > net Income
-3520
Annuals > 2 > income Statement > eps
-0.00017183304857212596
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
20485000
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-3520
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
-
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
-
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
144578
Annuals > 2 > balance Sheet > payables
-
Annuals > 2 > balance Sheet > short Term Debt
43106
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
166455
Annuals > 2 > balance Sheet > equity
-21877
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-3520
Annuals > 2 > cash Flow > depreciation
-
Annuals > 2 > cash Flow > change In Working Capital
-
Annuals > 2 > cash Flow > cash From Operations
-
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
-
Annuals > 2 > cash Flow > net Change In Cash
-
Annuals > 2 > cash Flow > currency_symbol
-
Annuals > 2 > ratios > PE
-0.00017183304857212596
Annuals > 2 > ratios > PB
-10843.182337614846
Annuals > 2 > ratios > ROE
16.089957489600952
Annuals > 2 > ratios > ROA
-2.4346719417892073
Annuals > 2 > ratios > FCF
-
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
35
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
-
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
43357
Annuals > 3 > income Statement > operating Income
-43357
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-43357
Annuals > 3 > income Statement > net Income
-43357
Annuals > 3 > income Statement > eps
-0.002116524286062973
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
20485000
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-43357
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
3
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
-
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
-
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
144281
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
36961
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
162638
Annuals > 3 > balance Sheet > equity
-18357
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-74.33
Annuals > 3 > cash Flow > depreciation
-
Annuals > 3 > cash Flow > change In Working Capital
-
Annuals > 3 > cash Flow > cash From Operations
-
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-
Annuals > 3 > cash Flow > net Change In Cash
-
Annuals > 3 > cash Flow > currency_symbol
-
Annuals > 3 > ratios > PE
-0.002116524286062973
Annuals > 3 > ratios > PB
-12922.389279294002
Annuals > 3 > ratios > ROE
236.18783025548836
Annuals > 3 > ratios > ROA
-30.05038778494743
Annuals > 3 > ratios > FCF
-
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
38
Valuation > metrics > PE
-1.9038240673784508
Valuation > metrics > PB
0.6094341168569509
Valuation > final Score
70
Valuation > verdict
39.1% Undervalued
Profitability > metrics > ROE
-10.019476158495634
Profitability > metrics > ROA
-9.402533560219323
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.08527647190508171
Risk > metrics > Interest Coverage
-11.5910912090502
Risk > final Score
14
Risk > verdict
High
Liquidity > metrics > Current Ratio
114.53561116458133
Liquidity > metrics > Quick Ratio
114.53561116458133
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
40
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-51
Prev Risks > 1
-30
Prev Risks > 2
19
Prev Liquidities > 0
100
Prev Liquidities > 1
45
Prev Liquidities > 2
42
Updated At
2026-01-20T21:27:38.636Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-12
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-1.03
Earnings History > 0 > eps Estimate
-0.34
Earnings History > 0 > eps Difference
-0.69
Earnings History > 0 > surprise Percent
-202.9412
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-09-03
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
0.0391
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-28
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.0207
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2024-12-31
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0.0831
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-09-30
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
0.0993
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-06-30
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0.0941
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-03-31
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0.0468
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
1
Buy
5
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of BridgeBio Oncology Therapeutics, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-1.03
EPS Estimate
-0.34
EPS Difference
-0.69
Surprise Percent
-202.9412%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.